NodThera
Treating chronic disease by targeting inflammation at its source
Treating chronic disease by targeting inflammation at its source
NodThera is a biotechnology startup with a mission to treat chronic diseases by addressing inflammation at its root cause. Founded in 2016, the company is focused on developing a new class of highly selective NLRP3 inflammasome inhibitors to combat diseases driven by chronic inflammation. With its headquarters in the United States and offices in Cambridge, UK; Seattle, WA; and Boston, MA, NodThera has been attracting attention for its innovative approach.
The company's most recent milestone includes a $55.00M Series B investment on 03 June 2020, with notable investors such as F-Prime Capital, Sofinnova Partners, 5AM Ventures, Cowen Digital, Epidarex Capital, Sanofi Ventures, and Novo Ventures participating in the funding round. This investment signifies confidence from prominent players in the industry, highlighting NodThera's potential for growth and development in the biotechnology and healthcare sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $55.00M | 7 |
|
03 Jun 2020 |
| Series A | $40.00M | 3 |
|
25 Jun 2018 |
No recent news or press coverage available for NodThera.
We care about your data, and we'd love to use cookies make your experience better.
